Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. Anderson as Head of Investor Relations and Public Relations, effective immediately.
In this position, Mr. Anderson will report directly to Rex Merchant, Anebulo’s Chief Financial Officer. Mr. Anderson will be responsible for Anebulo’s global investor relations and public relations programs. He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of information and data to these important stakeholders.
Mr. Anderson will build on Anebulo’s current investor relations and public relations programs to grow and diversify the Company's shareholder base as well as to enhance its communications with shareholders and other stakeholders. Scott will work closely with the management team to further develop the company's internal and external communications with a focus on strategy, branding, social media presence and investor communications.
Mr. Anderson brings more than 20 years of public company experience to Anebulo, having served in various investor relations and corporate communications roles at such companies as Qualcomm, Qorvo (formerly RF Micro Devices), Actavis plc (formerly Watson Pharmaceuticals), and O2Micro International Limited.
Commenting on the appointment, Dr. Daniel Schneeberger, CEO, said: "We are extremely pleased to welcome Scott to the Anebulo Team. His experience and insights make him ideally suited to support the continued development of our investor relations program and goals. Based on our plans to report topline results from our ongoing Phase 2 trial in the first half of the year, it is a great time to bolster our investor relations program and ensure best practices to drive shareholder value."
Mr. Anderson added, "I'm delighted to be joining Anebulo at this unique and exciting time. I look forward to assisting Anebulo to communicate the Company's strategic initiatives and performance drivers to the financial community and its key stakeholders."
Mr. Anderson earned a B.A. degree in Communication Arts & Sciences from the Annenberg School for Communication and Journalism at the University of Southern California.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1) with good oral bioavailability and brain penetration (rat brain:plasma ratio of approximately 1.5). Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated, and may lead to weight loss, an effect that is consistent with CB1 antagonism in the central nervous system. For further information about Anebulo, please visit www.anebulo.com.
This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, along with terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of Anebulo Pharmaceuticals and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including risks attendant to developing, testing and commercializing the company’s product candidates, and those described in Anebulo Pharmaceutical’s most recent annual report on Form 10-K and in other periodic reports filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.